Altimmune to Participate at Two Investor Conferences in March

On March 6, 2018 Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, reported that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (Press release, Altimmune, MAR 6, 2018, View Source [SID1234524432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

30th Annual ROTH Conference Presentation Details
Date: Tuesday, March 13
Time: 7:00pm Eastern Time/4:00pm Pacific Time
Location: The Ritz Carlton Orange County, Newport Beach, California – Salon 6

B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS)
Date: Saturday, March 17
Time: 8:30am China Time/7:30pm Eastern Time – Room A
Location: Intercontinental Hotel, Hangzhou, China

TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update

On March 6, 2018 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that a conference call will be held on Thursday March 8, 2018 to discuss results for the fourth quarter and year-end 2017, and provide a business outlook for 2018 (Press release, TG Therapeutics, MAR 6, 2018, View Source [SID1234524423]). Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Year-End 2017 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

Radius Health to Present at the Cowen 38th Annual Health Care Conference

On March 6, 2018 Radius Health, Inc. (Nasdaq:RDUS) reported that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen’s 38th Annual Health Care Conference on Monday, March 12, 2018 (Press release, Radius, MAR 6, 2018, View Source [SID1234524421]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information on the presentation is as follows:

Event: Cowen 38th Annual Health Care Conference
Date: Monday, March 12, 2018
Time: 3:30 p.m. EDT
Location: Dartmouth Room, 3rd Floor, Boston Marriott Copley Place, Boston, MA

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at View Source A replay of the webcast will be archived on Radius’ website for 30 days following the presentation.

Constellation Pharmaceuticals to Present at the 38th Annual Cowen and Company Health Care Conference

On March 6, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts (Press release, Constellation Pharmaceuticals, MAR 6, 2018, View Source [SID1234524412]). The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website

CLEVELAND BIOLABS REPORTS 2017 FINANCIAL RESULTS AND DEVELOPMENT PROGRESS

On March 6, 2018 Cleveland BioLabs, Inc. (NASDAQ:CBLI) reported that financial results and development progress for the fourth quarter and year ended December 31, 2017 (Filing, 8-K, Cleveland BioLabs, MAR 6, 2018, View Source [SID1234524411]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cleveland BioLabs reported a net loss, excluding minority interests, of $(1.2) million for the fourth quarter of 2017, or $(0.10) per share, compared to a net loss of $(1.2) million, or $(0.11) per share, for the fourth quarter of 2016. Net loss, excluding minority interests, for full year 2017 was $(9.7) million, or $(0.87) per share, compared to a net loss of $(2.7) million, or $(0.24) per share, for full year 2016.

As of December 31, 2017, the Company had $8.8 million in cash, cash equivalents and short-term investments, which, based on the Company’s current operational plan, is estimated to fund operations for at least one year beyond the filing date of our Form 10-K.

Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "The past year was one of substantial progress for the company and our Entolimod and Mobilan programs. We continued our pursuit of a pre- Emergency Use Authorization ("pre-EUA") with the U.S. Food and Drug Administration ("FDA") and submitted a Marketing Authorization Application ("MAA") with the European Medicines Agency ("EMA") for entolimod as a medical radiation countermeasure ("MRC"), and continued clinical exploration designed to further substantiate the potential of our Toll-like receptor 5 agonists, entolimod and Mobilan."

"The pursuit of approval by the FDA and EMA and commercialization of entolimod as a medical radiation countermeasure continue to be the company’s most important priorities and goals," continued Dr. Kogan. "Per FDA request and as part of its review of our pre-EUA application, we collated and submitted manufacturing information (Module 3) to the agency and initiated the in vivo biocomparability study in non-human primates, which is currently ongoing. Following completion of this study and discussion of the study results with the FDA, we expect the agency to resume review of our pre-EUA dossier".

"We are also pleased to announce submission in the European Union of a MAA for use of entolimod as a MRC," added Dr. Kogan. "Our application was recently validated by the EMA and is currently undergoing agency review. Filing of the MAA represents a significant milestone for the company and another major step toward making entolimod available worldwide as a life-saving and practical treatment of acute radiation syndrome for mass-casualty radiation and nuclear disaster scenarios."

Further Financial Results

Revenue for the fourth quarter of 2017 was $0.9 million compared to $1.0 million for the fourth quarter of 2016. Revenue for full year 2017 was $1.9 million compared to $3.5 million for full year 2016. The revenue changes are primarily due to decreased revenue from our MPT contracts at BioLab 612 and Panacela which were completed in 2016 partially offset by a slight increase in revenue from our DoD JWMRP contract.

Research and development (R&D) costs for the fourth quarter of 2017 were $1.5 million compared to $2.2 million for the fourth quarter of 2016. R&D costs for the full year 2017 decreased to $5.0 million compared to $6.5 million for the full year 2016. The research and development changes were primarily attributable to significant reductions of funds spent on Entolimod for oncology indication due to the completion of a clinical

study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naive patients with primary colorectal cancer, reduction in spending related to CBLB612 due to the completion of a clinical study in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy, and the
reduction in Panacela product candidate spending due to the completion of the active recruitment stage of the ongoing clinical studies with Mobilan. These reductions were partially offset by increased expenses on Entolimod’s biodefense indication for continued preclinical development along with other drug manufacturing activities associated with our JWMRP contract and expenses associated with our regulatory efforts with the EMA to prepare a pediatric investigational plan and other activities in support of filing a MAA with EMA.

General and administrative costs (G&A) for the fourth quarter of 2017 were $0.6 million compared to $0.7 million for the fourth quarter of 2016. G&A costs for full year 2017 decreased to $2.5 million compared to $3.4 million for full year 2016. These decreases were primarily attributable to reductions in personnel and outside professional costs.

At December 31, 2017 the Company had 11,279,834 shares of common stock outstanding. In addition, the Company has 211,487 shares of common stock reserved for issuance pursuant to outstanding stock options with a weighted average exercise price of $36.94 and 710,174 shares of common stock reserved for issuance pursuant to outstanding warrants exercisable at a weighted average price of $8.95.